Ovid Therapeutics (OVID) Current Leases (2022 - 2026)

Ovid Therapeutics has reported Current Leases for 5 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 7.28% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 7.28% YoY), and the FY2025 full-year result was $1.4 million, up 7.26% from the prior year.
• Current Leases for Q1 2026 stood at $1.5 million, up from $1.4 million in the prior quarter.
• The five-year high for Current Leases was $1.5 million in Q1 2026, with the low at $533946.0 in Q4 2022.
• Historically, Current Leases has averaged $1.2 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2023 — Current Leases jumped 133.36% — and 2025, when it advanced 7.2%.
• Ovid Therapeutics' Current Leases stood at $533946.0 in 2022, then jumped by 133.36% to $1.2 million in 2023, then climbed by 7.22% to $1.3 million in 2024, then increased by 7.26% to $1.4 million in 2025, then gained by 1.81% to $1.5 million in 2026.
• The last three Current Leases figures came in at $1.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.